D-Cure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
- Paid Up Capital ₹ 2.10 M
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 1185.00%
- Profit Growth -945.24%
- Ebitda -964.28%
- Net Worth -1167.88%
- Total Assets -41.24%
About D-Cure Pharmaceuticals
D-Cure Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2015 (Nine years and 11 months 18 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nayab Khatoon, Manju Bala, and Vijay Dinkar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2015PTC277682
- Company No.
277682
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2015
- Date of AGM
05 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at D-Cure Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nayab Khatoon  | Director | 09-Sep-2020 | Current |
| Manju Bala | Director | 09-Sep-2020 | Current |
| Vijay Dinkar | Director | 05-Jan-2022 | Current |
Financial Performance of D-Cure Pharmaceuticals.
D-Cure Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1185% increase. The company also saw a substantial fall in profitability, with a 945.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1167.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D-Cure Pharmaceuticals?
Unlock access to D-Cure Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at D-Cure Pharmaceuticals?
D-Cure Pharmaceuticals has a workforce of 16 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D-Cure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D-Cure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
